All updates
All updates
today 53文献与产业新闻精选评分4444 Roche’s Lunsumio delivers positive confirmatory trial readout in follicular lymphoma
中文产业新闻精选Chinese source评分6767 正大天晴HER2双抗ADC TQB2102治疗HER2低表达乳腺癌三期临床达到主要终点
中文产业新闻精选Chinese source评分6262 B7-H3靶向ADC药物Tam-Peli在小细胞肺癌中使死亡风险降低54%
中文产业新闻精选Chinese source评分6262 张磊/胡群/杨仁池/肖啸团队完成中国青少年血友病B基因治疗1期临床试验
文献与产业新闻精选评分4040 Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’
中文产业新闻精选Chinese source评分6060 君圣泰HTD1801在2026 ESC年会展示心-肾-代谢三轴临床获益
文献与产业新闻评分2727 WHO expresses cautious optimism about bid to control Ebola outbreak in DRC
文献与产业新闻精选评分4141 Vera’s strong phase 3 IgAN data for Trutakna intensify kidney disease rivalry
文献与产业新闻精选评分3535 Novartis ends ALS program after phase 2 flop, adding to R&D woes
NEJM评分00 Short or Long Antibiotic Regimens in Orthopedics
文献与产业新闻精选评分3737 Feasibility and Safety Profile of Non-anesthesiologist-administered Propofol During Colorectal Endoscopic Submucosal Dissection: A Single-center Study of 454 Procedures
文献与产业新闻精选评分3636 Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial
中文产业新闻精选Chinese source评分4747 Nature Medicine | 劲方医药GFH375（KRAS G12D抑制剂）I 期数据回顾：经多线治疗实体瘤展现积极疗效，支持多瘤种注册性临床
中文产业新闻精选Chinese source评分7979 依沃西单抗HARMONi-2 III期OS数据公布：中位30.个月，优于Keytruda
中文产业新闻精选Chinese source评分7373 依沃西单抗HARMONi-2 III期OS数据公布：对比K药达30.8 vs 22.6，11月迎关键节点
Cancer Cell精选评分5252 Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer
顶刊论文（社媒热度）精选评分5555 Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.
文献与产业新闻精选评分5353 STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
文献与产业新闻评分3838 Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
文献与产业新闻评分4343 J&J’s Contineum-partnered depression drug flunks another phase 2 test
文献与产业新闻精选评分5050 Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial
文献与产业新闻精选评分6262 Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial
中文产业新闻精选Chinese source评分6363 BioNTech/OncoC4新一代CTLA-4抗体gotistobart经治鳞状NSCLC三期mOS提升近一倍
中文产业新闻精选Chinese source评分5959 劲方医药GFH375治疗KRAS G12D突变型NSCLC II期数据入选2026 WCLC口头报告
文献与产业新闻精选评分5959 AZ’s camizestrant miss narrows oral SERD treatment settings
文献与产业新闻评分1717 STAT+: GSK touts lung cancer data from two drugs
文献与产业新闻评分2525 STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
文献与产业新闻评分2929 Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide
文献与产业新闻精选评分5757 STAT+: Definium’s LSD therapy eased anxiety in second large trial
文献与产业新闻评分4848 Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
中文产业新闻精选Chinese source评分7171 张力教授团队主导的TAISHAN-302研究在WCLC全体大会及NEJM发表，依康坦博妥塔单抗用于复发性小细胞肺癌二线治疗
顶刊论文（社媒热度）精选评分5757 Gastric Residual Volume Assessment in Critically Ill Children: The GASTRIC-PICU Randomized Clinical Trial.
中文产业新闻精选Chinese source评分7171 康方生物依沃西一线 NSCLC 头对头 K 药 OS 达到统计学显著性，中位 OS 30.8 个月
文献与产业新闻精选评分5050 Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
中文产业新闻精选Chinese source评分7474 DESTINY-Lung04三期显示德曲妥珠单抗一线治疗HER2突变晚期非小细胞肺癌中位PFS达14.3个月
中文产业新闻精选Chinese source评分6161 阿斯利康口服SERD camizestrant 一线乳腺癌3期SERENA-4未达PFS主要终点
中文产业新闻精选Chinese source评分6868 阿斯利康 Enhertu 肺癌三期 PFS 显著获益但初步总生存死亡风险升高 15%
中文产业新闻精选Chinese source评分7474 康方生物依沃西HARMONi-2三期对比帕博利珠单抗一线PD-L1阳性NSCLC达OS和PFS双阳性